Abstract:Gastrointestinal cancer has a high incidence in China, especially upper gastrointestinal cancer (esophageal and gastric cancer). Although the incidence has been declining in recent years, the annual incidence of new cases accounts for more than 50% of global cases, and the incidence of colorectal cancer in big cities like Beijing and Shanghai is increasing annually but the mortality rate has not yet increased significantly. Gradual implementation and promotion of multidisciplinary team (MDT) reduced the mortality of gastrointestinal tumors, but this change is not obvious. Successful clinical studies of immune checkpoint inhibitors [programmed death-1 (PD-1), programmed death ligand 1 (PD-L1)] for esophageal and gastric cancer have changed clinical treatment strategies. The overall survival of advanced patients has improved but the comprehensive treatment of locally advanced patients warrants further research. In addition to the microsatellite instability high (MSI-H) population, few drugs have changed the clinical outcome of colorectal cancer in the past decade, which makes it difficult to affect the prognosis of patients. Clinical research on MDT is difficult to conduct, resulting in less data accumulation in this field. The heterogeneity of gastrointestinal tumors is relatively strong and precise treatment should be the direction of future development. In this regard, several studies have been conducted and developed rapidly in recent years in China, including those on MSI-H, human epidermal growth factor receptor 2 (HER2), c-mesenchymal-epithelial transition factor (c-MET), B-Raf proto-oncogene serine/threonine kinase (BRAF), rat sarcoma virus (RAS), fibroblast growth factor receptors (FGFR) and polymerases epsilon (POLE). The selection of immunotherapy markers, as well as the discovery of efficacy and prognostic markers, are also clinicians' concerns. Several articles presented in this issue reflect the research carried out by Chinese researchers based on clinical problems. These concerns of clinicians would impact the clinical practice. However, due to the limitation of time and level, the findings cannot fully reflect the current level of gastrointestinal cancer research in China which is expected to develop rapidly in the future.

[Current problems and challenges in the diagnosis and treatment of colorectal cancer in China].

The Current Status of Treatment for Colorectal Cancer in China

Screening and prevention strategies for colorectal cancer

Current status of rectal cancer treatment in China

Current Status and Challenges of Gastrointestinal Cancer Treatment in China

The opportunity and challenge of colorectal surgery in China

Current status of surgical treatment of rectal cancer in China

Colorectal Cancer Screening in China: Status, Challenges, and Prospects — China, 2022

Clinical Bottlenecks of Individual Diagnosis and Treatment of Colorectal Cancer and Breakthrough Strategies

Global Trend of Colorectal Cancer, Prevention, and Control in China: Challenges and Strategies

Research on Colorectal Cancer in China

The 30 Years' Changes of Colorectal Cancer and the Strategies in China

Cancer screening in China: The current status, challenges, and suggestions

Problems and Countermeasures of Standardized Surgical Treatment for Colorectal Cancer

Epidemiology and early screening strategies for colorectal cancer in China.

The foci and problems in diagnosis and treatment of gastric cancer

Esophageal cancer in China: practice and research in the new era

Diagnosis and treatment of malignant tumors using integrated traditional and western medicine: Progress, challenges and reflections

The landscape of cancer research and cancer care in China

Epidemiology and risk factors of colorectal cancer in China

National Guidelines for Diagnosis and Treatment of Colorectal Cancer 2020 in China (english Version)